Magnus Unemo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7999597/publications.pdf

Version: 2024-02-01

415 papers	21,415 citations	15504 65 h-index	15732 125 g-index
430 all docs	430 docs citations	430 times ranked	9317 citing authors

#	Article	IF	Citations
1	No widespread dissemination of Chlamydia trachomatis diagnostic-escape variants and the impact of Neisseria gonorrhoeae positivity on the Aptima Combo 2 assay. Sexually Transmitted Infections, 2022, 98, 366-370.	1.9	3
2	Potential impact of the COVIDâ€19 pandemic on the national and regional incidence, epidemiology and diagnostic testing of chlamydia and gonorrhoea in Sweden, 2020. Apmis, 2022, 130, 34-42.	2.0	9
3	Gentamicin Susceptibility in Neisseria gonorrhoeae and Treatment Outcomes for Urogenital Gonorrhea After 25 Years of Sustained Gentamicin Use in Malawi. Sexually Transmitted Diseases, 2022, 49, 251-256.	1.7	9
4	Initial impacts of the COVID-19 pandemic on sexual and reproductive health service use and unmet need in Britain: findings from a quasi-representative survey (Natsal-COVID). Lancet Public Health, The, 2022, 7, e36-e47.	10.0	39
5	Intimate physical contact between people from different households during the COVID-19 pandemic: a mixed-methods study from a large, quasi-representative survey (Natsal-COVID). BMJ Open, 2022, 12, e055284.	1.9	15
6	Antimicrobial resistance prediction in Neisseria gonorrhoeae: current status and future prospects. Expert Review of Molecular Diagnostics, 2022, 22, 29-48.	3.1	18
7	OUP accepted manuscript. Journal of Antimicrobial Chemotherapy, 2022, , .	3.0	2
8	2021 European guideline on the management of Mycoplasma genitalium infections. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 641-650.	2.4	75
9	First reported lymphogranuloma venereum cases in Russia discovered in men who have sex with men attending proctologists. International Journal of STD and AIDS, 2022, , 095646242110727.	1.1	3
10	Gonococcal Clinical Strains Bearing a Common gdhR Single Nucleotide Polymorphism That Results in Enhanced Expression of the Virulence Gene lctP Frequently Possess a mtrR Promoter Mutation That Decreases Antibiotic Susceptibility. MBio, 2022, 13, e0027622.	4.1	4
11	First characterisation of antimicrobial susceptibility and resistance of Neisseria gonorrhoeae isolates in Qatar, 2017â€“2020. PLoS ONE, 2022, 17, e0264737.	2.5	5
12	Is the end of gonorrhoea in sight?. Lancet Infectious Diseases, The, 2022, 22, 919-921.	9.1	4
13	Pharmacodynamic Evaluation of Zoliflodacin Treatment of Neisseria gonorrhoeae Strains With Amino Acid Substitutions in the Zoliflodacin Target GyrB Using a Dynamic Hollow Fiber Infection Model. Frontiers in Pharmacology, 2022, 13, 874176.	3.5	15
14	Clinical Importance of Superior Sensitivity of the Aptima TMA-Based Assays for Mycoplasma genitalium Detection. Journal of Clinical Microbiology, 2022, 60, e0236921.	3.9	9
15	A Single Amino Acid Substitution in Elongation Factor G Can Confer Low-Level Gentamicin Resistance in Neisseria gonorrhoeae. Antimicrobial Agents and Chemotherapy, 2022, 66, e0025122.	3.2	4
16	Genomic surveillance and antimicrobial resistance in Neisseria gonorrhoeae isolates in Bangkok, Thailand in 2018. Journal of Antimicrobial Chemotherapy, 2022, , .	3.0	11
17	The European response to control and manage multi- and extensively drug-resistant Neisseria gonorrhoeae. Eurosurveillance, 2022, 27, .	7.0	8
18	Changes in testing and incidence of Chlamydia trachomatis and Neisseria gonorrhoeae â€“ the possible impact of the COVID-19 pandemic in the three Scandinavian countries. Infectious Diseases, 2022, 54, 623-631.	2.8	8

#	Article	IF	Citations
19	Extensively drug-resistant (XDR) Neisseria gonorrhoeae causing possible gonorrhoea treatment failure with ceftriaxone plus azithromycin in Austria, April 2022. Eurosurveillance, 2022, 27, .	7.0	35
20	National surveillance of Neisseria gonorrhoeae antimicrobial susceptibility and epidemiological data of gonorrhoea patients across Brazil, 2018â€“20. JAC-Antimicrobial Resistance, 2022, 4, .	2.1	6
21	Accurate, rapid, point-of-care tests for sexually transmitted infections. Lancet Infectious Diseases, The, 2021, 21, 584-586.	9.1	9
22	2020 European guideline on the management of syphilis. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 574-588.	2.4	159
23	Evaluation of the SpeeDxResistancePlusÂ®GC and SpeeDx GC 23S 2611 (beta) molecular assays for prediction of antimicrobial resistance/susceptibility to ciprofloxacin and azithromycin inNeisseria gonorrhoeae. Journal of Antimicrobial Chemotherapy, 2021, 76, 84-90.	3.0	10
24	Neisseria gonorrhoeaeSequence Typing for Antimicrobial Resistance (NG-STAR) clonal complexes are consistent with genomic phylogeny and provide simple nomenclature, rapid visualization and antimicrobial resistance (AMR) lineage predictions. Journal of Antimicrobial Chemotherapy, 2021, 76, 940-944.	3.0	22
25	High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinicalNeisseria gonorrhoeaeisolates from 25 European countries, 2018. Journal of Antimicrobial Chemotherapy, 2021, 76, 1221-1228.	3.0	31
26	Associations between antimicrobial susceptibility/resistance of Neisseria gonorrhoeae isolates in European Union/European Economic Area and patientsâ€™ gender, sexual orientation and anatomical site of infection, 2009â€“2016. BMC Infectious Diseases, 2021, 21, 273.	2.9	12
27	A community-driven resource for genomic epidemiology and antimicrobial resistance prediction of Neisseria gonorrhoeae at Pathogenwatch. Genome Medicine, 2021, 13, 61.	8.2	63
28	Pharmacodynamic Evaluation of Dosing, Bacterial Kill, and Resistance Suppression for Zoliflodacin Against Neisseria gonorrhoeae in a Dynamic Hollow Fiber Infection Model. Frontiers in Pharmacology, 2021, 12, 682135.	3.5	23
29	Antimicrobial resistance and molecular epidemiological typing of Neisseria gonorrhoeae isolates from Kyrgyzstan in Central Asia, 2012 and 2017. BMC Infectious Diseases, 2021, 21, 559.	2.9	4
30	Antimicrobial resistance in Neisseria gonorrhoeae isolates and gonorrhoea treatment in the Republic of Belarus, Eastern Europe, 2009â€“2019. BMC Infectious Diseases, 2021, 21, 520.	2.9	8
31	O01.8â€…Contemporary syphilis is characterised by rapid global spread of pandemic Treponema pallidum lineages. , 2021, , .		3
32	Lack of diagnostic-escape mutants of group B streptococcus in Slovenia. Clinical Microbiology and Infection, 2021, 27, 1054-1055.	6.0	3
33	Serum Complement Activation by C4BP-IgM Fusion Protein Can Restore Susceptibility to Antibiotics in Neisseria gonorrhoeae. Frontiers in Immunology, 2021, 12, 726801.	4.8	3
34	WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017â€“18: a retrospective observational study. Lancet Microbe, The, 2021, 2, e627-e636.	7.3	112
35	Antimicrobial susceptibility of Neisseria gonorrhoeae isolates and syndromic treatment of men with urethral discharge in Kingston, Jamaica, 2018â€“19. Journal of Antimicrobial Chemotherapy, 2021, , .	3.0	2
36	Genomic Epidemiology of Azithromycin-Nonsusceptible Neisseria gonorrhoeae, Argentina, 2005â€“2019. Emerging Infectious Diseases, 2021, 27, 2369-2378.	4.3	7

#	Article	IF	Citations
37	Implementation of a standardised and quality-assured enhanced gonococcal antimicrobial surveillance programme in accordance with WHO protocols in Kampala, Uganda. Sexually Transmitted Infections, 2021, 97, 312-316.	1.9	15
38	Background review for the â€˜2020 European guideline for the diagnosis and treatment of gonorrhoea in adultsâ€™. International Journal of STD and AIDS, 2021, 32, 108-126.	1.1	24
39	Global phylogeny of Treponema pallidum lineages reveals recent expansion and spread of contemporary syphilis. Nature Microbiology, 2021, 6, 1549-1560.	13.3	51
40	Gonorrhoea: a systematic review of prevalence reporting globally. BMC Infectious Diseases, 2021, 21, 1152.	2.9	30
41	First National Genomic Epidemiological Study of Neisseria gonorrhoeae Strains Spreading Across Sweden in 2016. Frontiers in Microbiology, 2021, 12, 820998.	3.5	8
42	Population-Level Antimicrobial Consumption Is Associated With Decreased Antimicrobial Susceptibility in Neisseria gonorrhoeae in 24 European Countries: An Ecological Analysis. Journal of Infectious Diseases, 2020, 221, 1107-1116.	4.0	37
43	Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and pharyngeal gonorrhoea: a randomized controlled trial. Clinical Microbiology and Infection, 2020, 26, 207-212.	6.0	25
44	Adherence to the 2012 European gonorrhoea guideline in the WHO European Region according to the 2018â€“19 International Union against Sexually Transmitted Infections European Collaborative Clinical Group gonorrhoea survey. International Journal of STD and AIDS, 2020, 31, 69-76.	1.1	14
45	The first wideâ€scale drug repurposing screen using the Prestwick Chemical Library (1200 bioactive) Tj ETQq1 1 0.784314 rgBT /Over and many additional drugs. Apmis, 2020, 128, 242-250.	2.0	11
46	The 2018â€“19 International Union against Sexually Transmitted Infections European Collaborative Clinical Group report on the diagnosis and treatment of gonorrhoea in Europe. International Journal of STD and AIDS, 2020, 31, 77-81.	1.1	8
47	Gonorrhoea treatment combined with population-level general cephalosporin and quinolone consumption may select for Neisseria gonorrhoeae antimicrobial resistance at the levels of NG-MAST genogroup: An ecological study in Europe. Journal of Global Antimicrobial Resistance, 2020, 23, 377-384.	2.2	10
48	High in vitro activity of DIS-73285, a novel antimicrobial with a new mechanism of action, against MDR and XDR Neisseria gonorrhoeae. Journal of Antimicrobial Chemotherapy, 2020, 75, 3244-3247.	3.0	3
49	Genomic epidemiology of Neisseria gonorrhoeae elucidating the gonococcal antimicrobial resistance and lineages/sublineages across Brazil, 2015â€“16. Journal of Antimicrobial Chemotherapy, 2020, 75, 3163-3172.	3.0	29
50	Antimicrobial resistance in Neisseria gonorrhoeae isolates from foreign-born population in the European Gonococcal Antimicrobial Surveillance Programme. Sexually Transmitted Infections, 2020, 96, 204-210.	1.9	7
51	A profile of the FDA-approved and CE/IVD-marked AptimaMycoplasma genitaliumassay (Hologic) and key priorities in the management ofM. genitaliuminfections. Expert Review of Molecular Diagnostics, 2020, 20, 1063-1074.	3.1	7
52	Developing target product profiles for Neisseria gonorrhoeae diagnostics in the context of antimicrobial resistance: An expert consensus. PLoS ONE, 2020, 15, e0237424.	2.5	21
53	Pharmacokinetic/pharmacodynamic considerations for new and current therapeutic drugs for uncomplicated gonorrhoeaâ€”challenges and opportunities. Clinical Microbiology and Infection, 2020, 26, 1630-1635.	6.0	16
54	Optimizations to keep gonorrhoea treatable and reduce antimicrobial resistance selection. Nature Reviews Urology, 2020, 17, 609-610.	3.8	2

#	Article	IF	Citations
55	Adaptation to the cervical environment is associated with increased antibiotic susceptibility in Neisseria gonorrhoeae. Nature Communications, 2020, 11, 4126.	12.8	51
56	2020 European guideline for the diagnosis and treatment of gonorrhoea in adults. International Journal of STD and AIDS, 2020, , 095646242094912.	1.1	109
57	Gonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019. Vaccine, 2020, 38, 4362-4373.	3.8	46
58	Call to action for health systems integration of point-of-care testing to mitigate the transmission and burden of sexually transmitted infections. Sexually Transmitted Infections, 2020, 96, 342-347.	1.9	39
59	Optimising treatments for sexually transmitted infections: surveillance, pharmacokinetics and pharmacodynamics, therapeutic strategies, and molecular resistance prediction. Lancet Infectious Diseases, The, 2020, 20, e181-e191.	9.1	27
60	Sensitivity, specificity, inclusivity and exclusivity of the updated Aptima Combo 2 assay, which provides detection coverage of the new diagnostic-escape Chlamydia trachomatis variants. BMC Infectious Diseases, 2020, 20, 419.	2.9	10
61	In vitro activity of the first-in-class triazaacenaphthylene gepotidacin alone and in combination with doxycycline against drug-resistant and -susceptible Mycoplasma genitalium. Emerging Microbes and Infections, 2020, 9, 1388-1392.	6.5	14
62	'Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and pharyngeal gonorrhoea' â€“ Authorâ€™s reply. Clinical Microbiology and Infection, 2020, 26, 799-800.	6.0	0
63	A Chlamydia trachomatis 23S rRNA G1523A variant escaping detection in the Aptima Combo 2 assay (Hologic) was widespread across Denmark in Julyâ€“September 2019. Apmis, 2020, 128, 440-444.	2.0	5
64	Bacterial vaginosis-associated vaginal microbiota is an age-independent risk factor for Chlamydia trachomatis, Mycoplasma genitalium and Trichomonas vaginalis infections in low-risk women, St. Petersburg, Russia. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 1221-1230.	2.9	31
65	Prevalence of Mycoplasma genitalium and Antibiotic Resistance-Associated Mutations in Patients at a Sexually Transmitted Infection Clinic in Iceland, and Comparison of the S-DiaMGTV and Aptima Mycoplasma genitalium Assays for Diagnosis. Journal of Clinical Microbiology, 2020, 58, .	3.9	8
66	Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2020, 20, 1302-1314.	9.1	154
67	Genomic evolution of Neisseria gonorrhoeae since the preantibiotic era (1928â€“2013): antimicrobial use/misuse selects for resistance and drives evolution. BMC Genomics, 2020, 21, 116.	2.8	57
68	Genomic analysis and antimicrobial resistance of Neisseria gonorrhoeae isolates from Vietnam in 2011 and 2015â€“16. Journal of Antimicrobial Chemotherapy, 2020, 75, 1432-1438.	3.0	28
69	Antimicrobial resistance in Mycoplasma genitalium sampled from the British general population. Sexually Transmitted Infections, 2020, 96, 464-468.	1.9	17
70	Prevalence and risk factors associated with Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium among women in Pelotas, Southern Brazil. International Journal of STD and AIDS, 2020, 31, 432-439.	1.1	9
71	Mutations in penicillin-binding protein 2 from cephalosporin-resistant Neisseria gonorrhoeae hinder ceftriaxone acylation by restricting protein dynamics. Journal of Biological Chemistry, 2020, 295, 7529-7543.	3.4	20
72	Genomic epidemiology and antimicrobial resistance determinants of Neisseria gonorrhoeae isolates from Ukraine, 2013â€“2018. Apmis, 2020, 128, 465-475.	2.0	13

#	Article	IF	Citations
73	Rise and fall of the new variant of Chlamydia trachomatis in Sweden: mathematical modelling study. Sexually Transmitted Infections, 2020, 96, 375-379.	1.9	6
74	Genomic and phenotypic characterisation of invasive neonatal and colonising group B Streptococcus isolates from Slovenia, 2001â€“2018. BMC Infectious Diseases, 2020, 20, 958.	2.9	9
75	Molecular epidemiological typing of Neisseria gonorrhoeae isolates identifies a novel association between genogroup G10557 (G7072) and decreased susceptibility to cefixime, Germany, 2014 to 2017. Eurosurveillance, 2020, 25, .	7.0	4
76	Validation of an Aptima-format Finnish new variant of Chlamydia trachomatis (FI-nvCT) surveillance assay, 2019. Eurosurveillance, 2020, 25, .	7.0	3
77	The Finnish New Variant of Chlamydia trachomatis with a Single Nucleotide Polymorphism in the 23S rRNA Target Escapes Detection by the Aptima Combo 2 Test. Microorganisms, 2019, 7, 227.	3.6	18
78	Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bulletin of the World Health Organization, 2019, 97, 548-562P.	3.3	985
79	Pathogenic Interplay Between Chlamydia trachomatis and Neisseria gonorrhoeae that Influences Management and Control Effortsâ€”More Questions than Answers?. Current Clinical Microbiology Reports, 2019, 6, 182-191.	3.4	16
80	The impact of antimicrobials on gonococcal evolution. Nature Microbiology, 2019, 4, 1941-1950.	13.3	91
81	World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts. Sexual Health, 2019, 16, 412.	0.9	177
82	2019 European guideline on the management of lymphogranuloma venereum. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1821-1828.	2.4	67
83	Antimicrobial resistance (AMR) and molecular characterization of Neisseria gonorrhoeae in Ghana, 2012-2015. PLoS ONE, 2019, 14, e0223598.	2.5	18
84	Genetic variation regulates the activation and specificity of Restriction-Modification systems in Neisseria gonorrhoeae. Scientific Reports, 2019, 9, 14685.	3.3	14
85	Diagnosing sexually transmitted infections in resourceâ€constrained settings: challenges and ways forward. Journal of the International AIDS Society, 2019, 22, e25343.	3.0	85
86	In vitro antimicrobial combination testing of and evolution of resistance to the first-in-class spiropyrimidinetrione zoliflodacin combined with six therapeutically relevant antimicrobials for Neisseria gonorrhoeae. Journal of Antimicrobial Chemotherapy, 2019, 74, 3521-3529.	3.0	24
87	High In Vitro Susceptibility to the First-in-Class Spiropyrimidinetrione Zoliflodacin among Consecutive Clinical Neisseria gonorrhoeae Isolates from Thailand and South Africa. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	11
88	Quantitation of all Four Gardnerella vaginalis Clades Detects Abnormal Vaginal Microbiota Characteristic of Bacterial Vaginosis More Accurately than Putative G.ÂvaginalisÂ SialidaseÂA Gene Count. Molecular Diagnosis and Therapy, 2019, 23, 139-147.	3.8	38
89	Antimicrobial Resistance in Neisseria gonorrhoeae and Treatment of Gonorrhea. Methods in Molecular Biology, 2019, 1997, 37-58.	0.9	71
90	Prediction of Minimum Inhibitory Concentrations of Antimicrobials for Neisseria gonorrhoeae Using Whole-Genome Sequencing. Methods in Molecular Biology, 2019, 1997, 59-76.	0.9	8

#	Article	IF	Citations
91	High prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae and particularly Trichomonas vaginalis diagnosed using US FDAâ€approved Aptima molecular tests and evaluation of conventional routine diagnostic tests in Ternopil, Ukraine. Apmis, 2019, 127, 627-634.	2.0	22
92	In vitro activity of the ketolide cethromycin in multidrug-resistant clinical Neisseria gonorrhoeae isolates and international reference strains. Journal of Chemotherapy, 2019, 31, 246-251.	1.5	2
93	Clonal expansion and spread of the ceftriaxone-resistant Neisseria gonorrhoeae strain FC428, identified in Japan in 2015, and closely related isolates. Journal of Antimicrobial Chemotherapy, 2019, 74, 1812-1819.	3.0	50
94	Now Is the Time to Implement Whole Genome Sequencing in the Global Antimicrobial Resistance Surveillance for Neisseria gonorrhoeae?. EClinicalMedicine, 2019, 7, 11-12.	7.1	1
95	Antimicrobial susceptibility of Neisseria gonorrhoeae isolates and treatment of gonorrhoea patients in Ternopil and Dnipropetrovsk regions of Ukraine, 2013â€“2018. Apmis, 2019, 127, 503-509.	2.0	24
96	Genome-based epidemiology and antimicrobial resistance determinants of Neisseria gonorrhoeae isolates with decreased susceptibility and resistance to extended-spectrum cephalosporins in Argentina in 2011â€“16. Journal of Antimicrobial Chemotherapy, 2019, 74, 1551-1559.	3.0	33
97	Ten years of external quality assessment (EQA) of Neisseria gonorrhoeae antimicrobial susceptibility testing in Europe elucidate high reliability of data. BMC Infectious Diseases, 2019, 19, 281.	2.9	14
98	The resurgence of syphilis in high-income countries in the 2000s: a focus on Europe. Epidemiology and Infection, 2019, 147, e143.	2.1	88
99	Collecting and exploiting data to understand a nationâ€™s sexual health needs: Implications for the British National Surveys of Sexual Attitudes and Lifestyles (Natsal). Sexually Transmitted Infections, 2019, 95, 159-161.	1.9	3
100	Emergence and Spread of Cephalosporin-ResistantNeisseria gonorrhoeaewith MosaicpenAAlleles, South Korea, 2012â€“2017. Emerging Infectious Diseases, 2019, 25, 416-424.	4.3	17
101	In vitro activity of the novel oral antimicrobial SMT-571, with a new mechanism of action, against MDR and XDR Neisseria gonorrhoeae: future treatment option for gonorrhoea?. Journal of Antimicrobial Chemotherapy, 2019, 74, 1591-1594.	3.0	13
102	P350â€...What is the optimum method for collecting robust data to understand a nationâ€™s sexual health needs?. , 2019, , .		0
103	P601â€...Macrolide and fluoroquinolone resistance-associated mutations inmycoplasma genitalium:a systematic review and meta-analysis. , 2019, , .		2
104	P637â€...Neisseria gonorrhoeaegenomic diversity in high risk groups in switzerland. , 2019, , .		0
105	P673â€...In-vitroactivity of SMT-571 and comparators against clinical isolates and reference strains ofneisseria gonorrhoeae. , 2019, , .		0
106	Prevalence, Macrolide Resistance, and Fluoroquinolone Resistance in Mycoplasma genitalium in Men Who Have Sex With Men Attending an Sexually Transmitted Disease Clinic in Dublin, Ireland in 2017â€“2018. Sexually Transmitted Diseases, 2019, 46, e35-e37.	1.7	17
107	Gonorrhoea. Nature Reviews Disease Primers, 2019, 5, 79.	30.5	284
108	The European gonococcal antimicrobial surveillance programme (Euro-GASP) appropriately reflects the antimicrobial resistance situation for Neisseria gonorrhoeae in the European Union/European Economic Area. BMC Infectious Diseases, 2019, 19, 1040.	2.9	27

#	Article	IF	Citations
109	Establishment of a Gonococcal Antimicrobial Surveillance Programme, in Accordance With World Health Organization Standards, in CÃ´te d'Ivoire, Western Africa, 2014â€“2017. Sexually Transmitted Diseases, 2019, 46, 179-184.	1.7	20
110	Aptima Trichomonas vaginalis assay elucidates significant underdiagnosis of trichomoniasis among women in Brazil according to an observational study. Sexually Transmitted Infections, 2019, 95, 129-132.	1.9	12
111	Pharmacokinetic considerations regarding the treatment of bacterial sexually transmitted infections with azithromycin: a review. Journal of Antimicrobial Chemotherapy, 2019, 74, 1157-1166.	3.0	56
112	Pharmacokinetic Data Are Predictive of In Vivo Efficacy for Cefixime and Ceftriaxone against Susceptible and Resistant Neisseria gonorrhoeae Strains in the Gonorrhea Mouse Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	33
113	Quantitative Proteomics of the 2016 WHO Neisseria gonorrhoeae Reference Strains Surveys Vaccine Candidates and Antimicrobial Resistance Determinants. Molecular and Cellular Proteomics, 2019, 18, 127-150.	3.8	35
114	C4BP-IgM protein as a therapeutic approach to treat Neisseria gonorrhoeae infections. JCI Insight, 2019, 4, .	5.0	23
115	Letter to the editor: Chlamydia trachomatis samples testing falsely negative in the Aptima Combo 2 test in Finland, 2019. Eurosurveillance, 2019, 24, .	7.0	13
116	Finnish new variant of Chlamydia trachomatis escaping detection in the Aptima Combo 2 assay also present in Ã–rebro County, Sweden, May 2019. Eurosurveillance, 2019, 24, .	7.0	15
117	The â€˜Finnish new variant of Chlamydia trachomatisâ€™ escaping detection in the Aptima Combo 2 assay is widespread across Norway, June to August 2019. Eurosurveillance, 2019, 24, .	7.0	10
118	Dual antimicrobial therapy for gonorrhoea: what is the role of azithromycin?. Lancet Infectious Diseases, The, 2018, 18, 486-488.	9.1	30
119	First nationwide antimicrobial susceptibility surveillance for Neisseria gonorrhoeae in Brazil, 2015â€“16. Journal of Antimicrobial Chemotherapy, 2018, 73, 1854-1861.	3.0	39
120	In Vivo -Selected Compensatory Mutations Restore the Fitness Cost of Mosaic penA Alleles That Confer Ceftriaxone Resistance in Neisseria gonorrhoeae. MBio, 2018, 9, .	4.1	51
121	In vitro activity of zoliflodacin (ETX0914) against macrolide-resistant, fluoroquinolone-resistant and antimicrobial-susceptible Mycoplasma genitalium strains. Journal of Antimicrobial Chemotherapy, 2018, 73, 1291-1294.	3.0	31
122	Macrolide and fluoroquinolone resistance in Mycoplasma genitalium in two Swedish counties, 2011â€“2015. Apmis, 2018, 126, 123-127.	2.0	20
123	Neisseria cinerea with High Ceftriaxone MIC Is a Source of Ceftriaxone and Cefixime Resistance-Mediating penA Sequences in Neisseria gonorrhoeae. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	37
124	Antimicrobial susceptibility in Neisseria gonorrhoeae isolates from five sentinel surveillance sites in Zimbabwe, 2015â€“2016. Sexually Transmitted Infections, 2018, 94, 62-66.	1.9	18
125	In Vitro Activity of Sitafloxacin and Additional Newer Generation Fluoroquinolones Against Ciprofloxacin-Resistant Neisseria gonorrhoeae Isolates. Microbial Drug Resistance, 2018, 24, 30-34.	2.0	12
126	Ten years transmission of the new variant of Chlamydia trachomatis in Sweden: prevalence of infections and associated complications. Sexually Transmitted Infections, 2018, 94, 100-104.	1.9	20

#	Article	IF	Citations
127	Clinical and analytical evaluation of the new Aptima Mycoplasma genitalium assay, with data on M.Âgenitalium prevalence and antimicrobial resistance in M.Âgenitalium in Denmark, Norway and Sweden in 2016. Clinical Microbiology and Infection, 2018, 24, 533-539.	6.0	74
128	In vitro activity and timeâ€kill curve analysis of sitafloxacin against a global panel of antimicrobialâ€resistant and multidrugâ€resistant Neisseria gonorrhoeae isolates. Apmis, 2018, 126, 29-37.	2.0	16
129	Multidrug-resistant Neisseria gonorrhoeae failing treatment with ceftriaxone and doxycycline in France, November 2017. Eurosurveillance, 2018, 23, .	7.0	84
130	Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018. Eurosurveillance, 2018, 23, .	7.0	255
131	Antimicrobial Susceptibility of Neisseria gonorrhoeae Isolates in YaoundÃ©, Cameroon From 2009 to 2014. Sexually Transmitted Diseases, 2018, 45, e101-e103.	1.7	5
132	WHO laboratory validation of Xpert^{Â®} CT/NG and Xpert^{Â®} TV on the GeneXpert system verifies high performances. Apmis, 2018, 126, 907-912.	2.0	45
133	Antibiotic resistance and NG-MAST sequence types of Neisseria gonorrhoeae isolates in Poland compared to the world. Postepy Dermatologii I Alergologii, 2018, 35, 546-551.	0.9	10
134	Antimicrobial resistance prediction and phylogenetic analysis of Neisseria gonorrhoeae isolates using the Oxford Nanopore MinION sequencer. Scientific Reports, 2018, 8, 17596.	3.3	59
135	Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in Neisseria gonorrhoeae in 25 European countries, 2016. BMC Infectious Diseases, 2018, 18, 609.	2.9	69
136	Performance characteristics of newer MIC gradient strip tests compared with the Etest for antimicrobial susceptibility testing of Neisseria gonorrhoeae. Apmis, 2018, 126, 822-827.	2.0	15
137	Public health surveillance of multidrug-resistant clones of Neisseria gonorrhoeae in Europe: a genomic survey. Lancet Infectious Diseases, The, 2018, 18, 758-768.	9.1	164
138	In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR Neisseria gonorrhoeae. Journal of Antimicrobial Chemotherapy, 2018, 73, 2072-2077.	3.0	50
139	Mismatch Amplification Mutation Assay-Based Real-Time PCR for Rapid Detection of Neisseria gonorrhoeae and Antimicrobial Resistance Determinants in Clinical Specimens. Journal of Clinical Microbiology, 2018, 56, .	3.9	26
140	Antimicrobial resistance and molecular epidemiology using whole-genome sequencing of Neisseria gonorrhoeae in Ireland, 2014â€“2016: focus on extended-spectrum cephalosporins and azithromycin. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 1661-1672.	2.9	36
141	Should we be testing for urogenital Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum in men and women? â€“ a position statement from the European <scp>STI</scp> Guidelines Editorial Board. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1845-1851.	2.4	148
142	Multidrug-resistant Neisseria gonorrhoeae isolate, belonging to the internationally spreading Japanese FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, Ireland, August 2018. Eurosurveillance, 2018, 23, .	7.0	80
143	Lymphogranuloma venereum (LGV) in men who have sex with men (MSM): a re-emerging problem, Malta, 2018. Eurosurveillance, 2018, 23, .	7.0	4
144	Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium. Nature Reviews Urology, 2017, 14, 139-152.	3.8	167

#	Article	IF	Citations
145	Alanine 501 Mutations in Penicillin-Binding Protein 2 from Neisseria gonorrhoeae: Structure, Mechanism, and Effects on Cephalosporin Resistance and Biological Fitness. Biochemistry, 2017, 56, 1140-1150.	2.5	39
146	Neisseria gonorrhoeae Sequence Typing for Antimicrobial Resistance, a Novel Antimicrobial Resistance Multilocus Typing Scheme for Tracking Global Dissemination of N. gonorrhoeae Strains. Journal of Clinical Microbiology, 2017, 55, 1454-1468.	3.9	147
147	Helicobacter pylori Adapts to Chronic Infection and Gastric Disease via pH-Responsive BabA-Mediated Adherence. Cell Host and Microbe, 2017, 21, 376-389.	11.0	104
148	A new rapid resazurin-based microdilution assay for antimicrobial susceptibility testing of Neisseria gonorrhoeae. Journal of Antimicrobial Chemotherapy, 2017, 72, 1961-1968.	3.0	32
149	Trichomonas vaginalis is very rare among women with vaginal discharge in Podlaskie province, Poland. Apmis, 2017, 125, 840-843.	2.0	6
150	Comprehensive global genome dynamics of Chlamydia trachomatis show ancient diversification followed by contemporary mixing and recent lineage expansion. Genome Research, 2017, 27, 1220-1229.	5.5	106
151	Role of Molecular Biology in Diagnosis and Characterization of Vulvo-Vaginitis in Clinical Practice. Ginecologic and Obstetric Investigation, 2017, 82, 607-616.	1.6	7
152	P3.157â€...Does the european gonococcal antimicrobial surveillance programme (EURO-GASP) accurately reflect the true antimicrobial resistance situation in europe?. , 2017, , .		1
153	Genomic Characterization of Urethritis-Associated Neisseria meningitidis Shows that a Wide Range of N. meningitidis Strains Can Cause Urethritis. Journal of Clinical Microbiology, 2017, 55, 3374-3383.	3.9	24
154	In Vitro Activity of the Novel Pleuromutilin Lefamulin (BC-3781) and Effect of Efflux Pump Inactivation on Multidrug-Resistant and Extensively Drug-Resistant Neisseria gonorrhoeae. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	48
155	Proof of principle for effectiveness of a gonorrhoea vaccine. Nature Reviews Urology, 2017, 14, 643-644.	3.8	14
156	Performance and operational characteristics of point-of-care tests for the diagnosis of urogenital gonococcal infections. Sexually Transmitted Infections, 2017, 93, S16-S21.	1.9	39
157	Systematic reviews of point-of-care tests for the diagnosis of urogenitalChlamydia trachomatisinfections. Sexually Transmitted Infections, 2017, 93, S22-S30.	1.9	46
158	Rapid accurate point-of-care tests combining diagnostics and antimicrobial resistance prediction forNeisseria gonorrhoeaeandMycoplasma genitalium. Sexually Transmitted Infections, 2017, 93, S65-S68.	1.9	38
159	Sexually transmitted infections: challenges ahead. Lancet Infectious Diseases, The, 2017, 17, e235-e279.	9.1	510
160	Recent advances in the development and use of molecular tests to predict antimicrobial resistance inNeisseria gonorrhoeae. Expert Review of Molecular Diagnostics, 2017, 17, 845-859.	3.1	61
161	Prevalence of macrolide and fluoroquinolone resistance-mediating mutations in Mycoplasma genitalium in five cities in Russia and Estonia. PLoS ONE, 2017, 12, e0175763.	2.5	39
162	Fitness cost and benefit of antimicrobial resistance in Neisseria gonorrhoeae: Multidisciplinary approaches are needed. PLoS Medicine, 2017, 14, e1002423.	8.4	5

#	Article	IF	Citations
163	O01.1â€...A tale of two halves; low extended-spectrum cephalosporin and high azithromycin resistance inneisseria gonorrhoeaein europe, 2015. , 2017, , .		0
164	Mycoplasma genitalium: whole genome sequence analysis, recombination and population structure. BMC Genomics, 2017, 18, 993.	2.8	35
165	Overall Low Extended-Spectrum Cephalosporin Resistance but high Azithromycin Resistance in Neisseria gonorrhoeae in 24 European Countries, 2015. BMC Infectious Diseases, 2017, 17, 617.	2.9	90
166	P1.59â€...Genomic characterisation of urethritis-associatedneisseria meningitidis. , 2017, , .		0
167	LB1.69â€...Clinical and analytical evaluation of the new aptimamycoplasma genitaliumassay on the panther instrument (HOLOGIC),m. genitaliumprevalence, and antimicrobial resistance inm. genitaliumin sweden, denmark and norway in 2016. , 2017, , .		0
168	Trichomonas vaginalis is Rare Among Women in Iceland. Acta Dermato-Venereologica, 2017, 97, 1258-1260.	1.3	5
169	Antimicrobial resistance in Neisseria gonorrhoeae: Global surveillance and a call for international collaborative action. PLoS Medicine, 2017, 14, e1002344.	8.4	481
170	Multidrug-resistant gonorrhea: A research and development roadmap to discover new medicines. PLoS Medicine, 2017, 14, e1002366.	8.4	129
171	Multidrug-resistant Neisseria gonorrhoeae infection with ceftriaxone resistance and intermediate resistance to azithromycin, Denmark, 2017. Eurosurveillance, 2017, 22, .	7.0	83
172	Antimicrobial Resistance Expressed by Neisseria gonorrhoeae: A Major Global Public Health Problem in the 21st Century. , 2016, , 213-237.		5
173	P141â€...A service evaluation for and on behalf of the European Clinical Collaborative Group (ECCG) - The management of Gonorrhoea across Europe. Sexually Transmitted Infections, 2016, 92, A68.3-A69.	1.9	0
174	Molecular tests for the detection of antimicrobial resistant Neisseria gonorrhoeae. Current Opinion in Infectious Diseases, 2016, 29, 45-51.	3.1	51
175	Multiplex Real-Time PCR Assay with High-Resolution Melting Analysis for Characterization of Antimicrobial Resistance in Neisseria gonorrhoeae. Journal of Clinical Microbiology, 2016, 54, 2074-2081.	3.9	33
176	New Ceftriaxone- and Multidrug-Resistant Neisseria gonorrhoeae Strain with a Novel Mosaic penA Gene Isolated in Japan. Antimicrobial Agents and Chemotherapy, 2016, 60, 4339-4341.	3.2	146
177	Genomic Epidemiology and Molecular Resistance Mechanisms of Azithromycin-Resistant Neisseria gonorrhoeae in Canada from 1997 to 2014. Journal of Clinical Microbiology, 2016, 54, 1304-1313.	3.9	124
178	Test of Cure for Anogenital Gonorrhoea Using Modern RNA-Based and DNA-Based Nucleic Acid Amplification Tests: A Prospective Cohort Study. Clinical Infectious Diseases, 2016, 62, 1348-1355.	5.8	27
179	Gentamicinin vitroactivity and tentative gentamicin interpretation criteria for the CLSI and calibrated dichotomous sensitivity disc diffusion methods forNeisseria gonorrhoeae. Journal of Antimicrobial Chemotherapy, 2016, 71, 1856-1859.	3.0	17
180	Evaluation and subsequent optimizations of the quantitative AmpliSens Florocenosis/Bacterial vaginosisâ€<scp>FRT</scp> multiplex realâ€time <scp>PCR</scp> assay for diagnosis of bacterial vaginosis. Apmis, 2016, 124, 1099-1108.	2.0	15

#	Article	IF	Citations
181	Proteomics-driven Antigen Discovery for Development of Vaccines Against Gonorrhea. Molecular and Cellular Proteomics, 2016, 15, 2338-2355.	3.8	82
182	Protection against genital tract Chlamydia trachomatis infection following intranasal immunization with a novel recombinant <scp>MOMP VS</scp>2/4 antigen. Apmis, 2016, 124, 1078-1086.	2.0	6
183	Antimicrobial resistance and Neisseria gonorrhoeae multiantigen sequence typing (NG-MAST) genotypes in N. gonorrhoeae during 2012â€“2014 in Karachi, Pakistan. BMC Infectious Diseases, 2016, 16, 353.	2.9	10
184	WGS analysis and molecular resistance mechanisms of azithromycin-resistant (MIC >2) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 627 Td Chemotherapy, 2016, 71, 3109-3116.	3.0	81
185	The novel 2016 WHONeisseria gonorrhoeaereference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization. Journal of Antimicrobial Chemotherapy, 2016, 71, 3096-3108.	3.0	246
186	Efflux Pumps in Neisseria gonorrhoeae: Contributions to Antimicrobial Resistance and Virulence. , 2016, , 439-469.		10
187	Antimicrobial susceptibility testing of Neisseria gonorrhoeae isolates in Pakistan by Etest compared to Calibrated Dichotomous Sensitivity and Clinical Laboratory Standards Institute disc diffusion techniques. BMC Microbiology, 2016, 16, 236.	3.3	11
188	Time-kill curve analysis and pharmacodynamic modelling for in vitro evaluation of antimicrobials against Neisseria gonorrhoeae. BMC Microbiology, 2016, 16, 216.	3.3	81
189	Time to clearance of Chlamydia trachomatis RNA and DNA after treatment in patients coinfected with Neisseria gonorrhoeae â€“ a prospective cohort study. BMC Infectious Diseases, 2016, 16, 554.	2.9	21
190	Antimicrobial Resistance Expressed by Neisseria gonorrhoeae : A Major Global Public Health Problem in the 21st Century. Microbiology Spectrum, 2016, 4, .	3.0	178
191	Frequency and typing of Propionibacterium acnes in prostate tissue obtained from men with and without prostate cancer. Infectious Agents and Cancer, 2016, 11, 26.	2.6	63
192	Syphilis epidemiology in 1994â€“2013, molecular epidemiological strain typing and determination of macrolide resistance in Treponema pallidum in 2013â€“2014 in Tuva Republic, Russia. Apmis, 2016, 124, 595-602.	2.0	23
193	Failure of Dual Antimicrobial Therapy in Treatment of Gonorrhea. New England Journal of Medicine, 2016, 374, 2504-2506.	27.0	283
194	A Novel Factor Hâ€“Fc Chimeric Immunotherapeutic Molecule against Neisseria gonorrhoeae. Journal of Immunology, 2016, 196, 1732-1740.	0.8	35
195	2015 European guideline on the management of Chlamydia trachomatis infections. International Journal of STD and AIDS, 2016, 27, 333-348.	1.1	239
196	First nationwide study regarding ceftriaxone resistance and molecular epidemiology ofNeisseria gonorrhoeaein China. Journal of Antimicrobial Chemotherapy, 2016, 71, 92-99.	3.0	47
197	Syphilis in females in Bialystok, Poland, 2000-2015. Przeglad Epidemiologiczny, 2016, 70, 273-280.	0.2	2
198	Late-stage parenchymatous neurosyphilis presenting as general paresis of insane, Poland â€“ case report. Przeglad Epidemiologiczny, 2016, 70, 585-592.	0.2	0

#	Article	IF	Citations
199	Emergence and evolution of internationally disseminated cephalosporin-resistant Neisseria gonorrhoeae clones from 1995 to 2005 in Japan. BMC Infectious Diseases, 2015, 15, 378.	2.9	63
200	003.6â€...Timing of test of cure for anogenitalneisseria gonorrhoeaeinfections - a prospective cohort study using nucleic acid amplification tests. Sexually Transmitted Infections, 2015, 91, A32.1-A32.	1.9	0
201	006.2â€...High in vitro susceptibility to the novel spiropyrimidinetrione azd0914 among 873 contemporary clinical neisseria gonorrhoeae isolates in 21 european countries during 2012â€“2014. Sexually Transmitted Infections, 2015, 91, A37.3-A38.	1.9	0
202	009.1â€...Standardised, quality assured time-kill curve analysis and pharmacodynamic functions of different antibiotics forin vitroevaluation of treatment regimens forneisseria gonorrhoeae. Sexually Transmitted Infections, 2015, 91, A44.3-A45.	1.9	0
203	009.2â€...Establishment of the gonorrhoea mouse model for pre-clinical testing of antimicrobial agents againstneisseria gonorrhoeae. Sexually Transmitted Infections, 2015, 91, A45.1-A45.	1.9	0
204	Analytical specificity and sensitivity of the novel dualâ€target GeneProofÂNeisseria gonorrhoeae <scp>PCR</scp> kit for detection of N. gonorrhoeae. Apmis, 2015, 123, 955-958.	2.0	3
205	Analytical evaluation of nine serological assays for diagnosis of syphilis. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2369-2376.	2.4	17
206	Genetic Resistance Determinants, In Vitro Time-Kill Curve Analysis and Pharmacodynamic Functions for the Novel Topoisomerase II Inhibitor ETX0914 (AZD0914) in Neisseria gonorrhoeae. Frontiers in Microbiology, 2015, 6, 1377.	3.5	44
207	Population structure ofNeisseria gonorrhoeaebased on whole genome data and its relationship with antibiotic resistance. PeerJ, 2015, 3, e806.	2.0	67
208	Successful Combination of Nucleic Acid Amplification Test Diagnostics and Targeted Deferred Neisseria gonorrhoeae Culture. Journal of Clinical Microbiology, 2015, 53, 1884-1890.	3.9	23
209	Five-day Azithromycin Treatment Regimen for Mycoplasma genitalium Infection Also Effectively Eradicates Chlamydia trachomatis. Acta Dermato-Venereologica, 2015, 95, 730-732.	1.3	19
210	Background review for the â€˜2015 European guideline on the management ofChlamydia trachomatisinfectionsâ€™. International Journal of STD and AIDS, 2015, , 095646241561883.	1.1	23
211	In vitro activities of the novel bicyclolides modithromycin (EDP-420, EP-013420, S-013420) and EDP-322 against MDR clinical Neisseria gonorrhoeae isolates and international reference strains. Journal of Antimicrobial Chemotherapy, 2015, 70, 173-177.	3.0	17
212	In Vitro Activity of Fosfomycin Alone and in Combination with Ceftriaxone or Azithromycin against Clinical Neisseria gonorrhoeae Isolates. Antimicrobial Agents and Chemotherapy, 2015, 59, 1605-1611.	3.2	45
213	Will Genome Analysis Elucidate Evolution, Global Transmission and Virulence of Neisseria Meningitidis Lineages?. EBioMedicine, 2015, 2, 186-187.	6.1	3
214	Trichomonas vaginalis Infections are Rare Among Young Patients Attending an STI Clinic in Sweden. Acta Dermato-Venereologica, 2015, 95, 343-344.	1.3	9
215	Emergence of decreased susceptibility and resistance to extended-spectrum cephalosporins inNeisseria gonorrhoeaein Korea. Journal of Antimicrobial Chemotherapy, 2015, 70, 2536-2542.	3.0	33
216	Future treatment of gonorrhoea â€“ novel emerging drugs are essential and in progress?. Expert Opinion on Emerging Drugs, 2015, 20, 357-360.	2.4	13

#	Article	IF	Citations
217	Genome-Based Characterization of Emergent Invasive Neisseria meningitidis Serogroup Y Isolates in Sweden from 1995 to 2012. Journal of Clinical Microbiology, 2015, 53, 2154-2162.	3.9	25
218	Antimicrobial susceptibility/resistance and NG-MAST characterisation of Neisseria gonorrhoeae in Belarus, Eastern Europe, 2010â€“2013. BMC Infectious Diseases, 2015, 15, 29.	2.9	29
219	Treatment efficacy, treatment failures and selection of macrolide resistance in patients with high load of Mycoplasma genitalium during treatment of male urethritis with josamycin. BMC Infectious Diseases, 2015, 15, 40.	2.9	66
220	Prospects of untreatable gonorrhea and ways forward. Future Microbiology, 2015, 10, 313-316.	2.0	14
221	Detailed characterization of the first high-level azithromycin-resistant Neisseria gonorrhoeae cases in Ireland. Journal of Antimicrobial Chemotherapy, 2015, 70, 2411-2413.	3.0	25
222	Current and future antimicrobial treatment of gonorrhoea â€“ the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infectious Diseases, 2015, 15, 364.	2.9	214
223	Evaluation of the New BD Max GC Real-Time PCR Assay, Analytically and Clinically as a Supplementary Test for the BD ProbeTec GC Qx Amplified DNA Assay, for Molecular Detection of Neisseria gonorrhoeae. Journal of Clinical Microbiology, 2015, 53, 3935-3937.	3.9	7
224	Evaluation of the new AmpliSens multiplex realâ€time <scp>PCR</scp> assay for simultaneous detection of NeisseriaÂgonorrhoeae, ChlamydiaÂtrachomatis, MycoplasmaÂgenitalium, and TrichomonasÂvaginalis. Apmis, 2015, 123, 879-886.	2.0	46
225	Is the tide turning again for cephalosporin resistance in Neisseria gonorrhoeae in Europe? Results from the 2013 European surveillance. BMC Infectious Diseases, 2015, 15, 321.	2.9	44
226	High In Vitro Susceptibility to the Novel Spiropyrimidinetrione ETX0914 (AZD0914) among 873 Contemporary Clinical Neisseria gonorrhoeae Isolates from 21 European Countries from 2012 to 2014. Antimicrobial Agents and Chemotherapy, 2015, 59, 5220-5225.	3.2	42
227	Genetic diversity ofbla_{TEM}alleles, antimicrobial susceptibility and molecular epidemiological characteristics of penicillinase-producingNeisseria gonorrhoeaefrom England and Wales. Journal of Antimicrobial Chemotherapy, 2015, 70, dkv260.	3.0	16
228	Antibiotic susceptibility of Propionibacterium acnes isolated from orthopaedic implant-associated infections. Anaerobe, 2015, 32, 57-62.	2.1	37
229	Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting. PLoS ONE, 2015, 10, e0143304.	2.5	1,227
230	Utilizing CMP-Sialic Acid Analogs to Unravel Neisseria gonorrhoeae Lipooligosaccharide-Mediated Complement Resistance and Design Novel Therapeutics. PLoS Pathogens, 2015, 11, e1005290.	4.7	53
231	Clinical and epidemiological characteristics of males with syphilis in BiaÅ‚ystok, Poland in 2008-2013. Przeglad Epidemiologiczny, 2015, 69, 41-5, 143-6.	0.2	2
232	The '2015 European guideline on the management of Chlamydia trachomatis infections' has now been published. Eurosurveillance, 2015, 20, 30080.	7.0	0
233	2012 European guideline on the diagnosis and treatment of gonorrhoea in adults*. Przeglad Dermatologiczny, 2014, 2, 168-178.	0.1	3
234	Challenges with antimicrobial susceptibility testing forNeisseria gonorrhoeaein the era of extensively drug-resistant gonorrhoea â€” molecular antimicrobial resistance testing crucial. Pathogens and Global Health, 2014, 108, 214-215.	2.3	5

#	Article	IF	Citations
235	Molecular Diagnostics for Gonorrhoea: Implications for Antimicrobial Resistance and the Threat of Untreatable Gonorrhoea. PLoS Medicine, 2014, 11, e1001598.	8.4	56
236	First antimicrobial resistance data and genetic characteristics of Neisseria gonorrhoeae isolates from Estonia, 2009â€“2013. New Microbes and New Infections, 2014, 2, 150-153.	1.6	6
237	First Three Neisseria gonorrhoeae Isolates with High-Level Resistance to Azithromycin in Sweden: a Threat to Currently Available Dual-Antimicrobial Regimens for Treatment of Gonorrhea?. Antimicrobial Agents and Chemotherapy, 2014, 58, 624-625.	3.2	56
238	Mitigating the Emergence and Spread of Multidrug- and Extensively Drug-Resistant Gonorrhea. Sexually Transmitted Diseases, 2014, 41, 238-239.	1.7	8
239	Holistic actions are essential to combat the global public health burden of non-viral sexually transmitted infections: challenges and future perspectives. Expert Review of Anti-Infective Therapy, 2014, 12, 649-651.	4.4	0
240	Phenotypic and molecular characterization of Neisseria gonorrhoeae isolates from Slovenia, 2006-12: rise and fall of the multidrug-resistant NG-MAST genogroup 1407 clone?. Journal of Antimicrobial Chemotherapy, 2014, 69, 1517-1525.	3.0	33
241	Risk Factors for Antimicrobial-Resistant Neisseria gonorrhoeae in Europe. Sexually Transmitted Diseases, 2014, 41, 723-729.	1.7	33
242	Plasmid deficiency in urogenital isolates ofChlamydia trachomatisreduces infectivity and virulence in a mouse model. Pathogens and Disease, 2014, 70, 61-69.	2.0	58
243	High In Vitro Activity of the Novel Spiropyrimidinetrione AZD0914, a DNA Gyrase Inhibitor, against Multidrug-Resistant Neisseria gonorrhoeae Isolates Suggests a New Effective Option for Oral Treatment of Gonorrhea. Antimicrobial Agents and Chemotherapy, 2014, 58, 5585-5588.	3.2	62
244	Phylogenomics for drug-resistant Neisseria gonorrhoeae. Lancet Infectious Diseases, The, 2014, 14, 179-180.	9.1	9
245	Antimicrobial susceptibility/resistance and genetic characteristics of Neisseria gonorrhoeaeisolates from Poland, 2010-2012. BMC Infectious Diseases, 2014, 14, 65.	2.9	18
246	Treatment failure with 2 g of azithromycin (extended-release formulation) in gonorrhoea in Japan caused by the international multidrug-resistant ST1407 strain of Neisseria gonorrhoeae. Journal of Antimicrobial Chemotherapy, 2014, 69, 2086-2090.	3.0	26
247	Importance of Multidrug Efflux Pumps in the Antimicrobial Resistance Property of Clinical Multidrug-Resistant Isolates of Neisseria gonorrhoeae. Antimicrobial Agents and Chemotherapy, 2014, 58, 3556-3559.	3.2	96
248	Decreased susceptibility to chlorhexidine and prevalence of disinfectant resistance genes among clinical isolates of <scp>S</scp>taphylococcus epidermidis. Apmis, 2014, 122, 961-967.	2.0	43
249	Antimicrobial resistance, genetic resistance determinants for ceftriaxone and molecular epidemiology of Neisseria gonorrhoeae isolates in Nanjing, China. Journal of Antimicrobial Chemotherapy, 2014, 69, 2959-2965.	3.0	35
250	In Vitro Activity of the New Fluoroketolide Solithromycin (CEM-101) against Macrolide-Resistant and -Susceptible Mycoplasma genitalium Strains. Antimicrobial Agents and Chemotherapy, 2014, 58, 3151-3156.	3.2	59
251	Verified clinical failure with cefotaxime 1g for treatment of gonorrhoea in the Netherlands: a case report. Sexually Transmitted Infections, 2014, 90, 513-514.	1.9	14
252	Russian gonococcal antimicrobial susceptibility programme (RU-GASP) â€“ resistance in Neisseria gonorrhoeae during 2009â€“2012 and NG-MAST genotypes in 2011 and 2012. BMC Infectious Diseases, 2014, 14, 342.	2.9	28

#	Article	IF	Citations
253	Characterisation of bla TEM genes and types of Î²-lactamase plasmids in Neisseria gonorrhoeae â€“ the prevalent and conserved bla TEM-135 has not recently evolved and existed in the Toronto plasmid from the origin. BMC Infectious Diseases, 2014, 14, 454.	2.9	57
254	Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future. Clinical Microbiology Reviews, 2014, 27, 587-613.	13.6	894
255	High in vitro activity of a novel dual bacterial topoisomerase inhibitor of the ATPase activities of GyrB and ParE (VT12-008911) against Neisseria gonorrhoeae isolates with various high-level antimicrobial resistance and multidrug resistance. Journal of Antimicrobial Chemotherapy, 2014, 69, 1866-1872.	3.0	19
256	Challenges with gonorrhea in the era of multi-drug and extensively drug resistance â€“ are we on the right track?. Expert Review of Anti-Infective Therapy, 2014, 12, 653-656.	4.4	30
257	Four treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 mg) or cefotaxime (500 mg), Sweden, 2013 and 2014. Eurosurveillance, 2014, 19, .	7.0	49
258	Emerging cephalosporin and multidrug-resistant gonorrhoea in Europe. Eurosurveillance, 2014, 19, 20955.	7.0	26
259	The â€˜2014 European guideline on the management of syphilisâ€™ has now been published. Eurosurveillance, 2014, 19, 20957.	7.0	2
260	Most but not all laboratories can detect the recently emerged Neisseria gonorrhoeae porA mutants â€“ results from the QCMD 2013 N. gonorrhoeae external quality assessment programme. Eurosurveillance, 2014, 19, 20711.	7.0	6
261	Sexual behaviours, knowledge and attitudes regarding safe sex, and prevalence of nonâ€viral sexually transmitted infections among attendees of youth clinics in St. Petersburg, Russia. Journal of the European Academy of Dermatology and Venereology, 2013, 27, e75-84.	2.4	7
262	Evaluation of polymerase chain reaction assays for the diagnosis of Trichomonas vaginalis infection in Russia. Journal of the European Academy of Dermatology and Venereology, 2013, 27, e217-23.	2.4	11
263	Antimicrobial susceptibility and genetic characteristics of Neisseria gonorrhoeae isolates from Vietnam, 2011. BMC Infectious Diseases, 2013, 13, 40.	2.9	54
264	Antimicrobial susceptibility and genetic characteristics of Neisseria gonorrhoeae isolates from India, Pakistan and Bhutan in 2007â€“2011. BMC Infectious Diseases, 2013, 13, 35.	2.9	24
265	Current and future treatment options for gonorrhoea: TableÂ1. Sexually Transmitted Infections, 2013, 89, iv52-iv56.	1.9	35
266	Comparison of Staphylococcus epidermidis isolated from prosthetic joint infections and commensal isolates in regard to antibiotic susceptibility, agr type, biofilm production, and epidemiology. International Journal of Medical Microbiology, 2013, 303, 32-39.	3.6	80
267	Neisseria gonorrhoeae Strain with High-Level Resistance to Spectinomycin Due to a Novel Resistance Mechanism (Mutated Ribosomal Protein S5) Verified in Norway. Antimicrobial Agents and Chemotherapy, 2013, 57, 1057-1061.	3.2	74
268	Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin-resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. Journal of Antimicrobial Chemotherapy, 2013, 68, 1267-1270.	3.0	108
269	The European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP)â€”a sentinel approach in the European Union (EU)/European Economic Area (EEA). Sexually Transmitted Infections, 2013, 89, iv16-iv18.	1.9	39
270	Staphylococcal cassette chromosome mec (SCCmec) and arginine catabolic mobile element (ACME) in Staphylococcus epidermidis isolated from prosthetic joint infections. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 691-697.	2.9	15

#	Article	IF	Citations
271	Prevalence and Molecular Epidemiological Typing of Penicillinase-Producing Neisseria gonorrhoeae and Their blaTEM-135 Gene Variants in Nanjing, China. Sexually Transmitted Diseases, 2013, 40, 872-876.	1.7	20
272	Gonorrhoea and gonococcal antimicrobial resistance surveillance networks in the WHO European Region, including the independent countries of the former Soviet Union. Sexually Transmitted Infections, 2013, 89, iv42-iv46.	1.9	34
273	Does the â€˜2012 IUSTI ECCG report on the diagnosis and management of Neisseria gonorrhoeae infections in Europeâ€™ depict the situation in Europe?. International Journal of STD and AIDS, 2013, 24, 423-426.	1.1	6
274	Innate Recognition by Neutrophil Granulocytes Differs between Neisseria gonorrhoeae Strains Causing Local or Disseminating Infections. Infection and Immunity, 2013, 81, 2358-2370.	2.2	28
275	2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. International Journal of STD and AIDS, 2013, 24, 85-92.	1.1	371
276	Antimicrobial Resistance and Molecular Typing of Neisseria gonorrhoeae Isolates in Kyoto and Osaka, Japan, 2010 to 2012: Intensified Surveillance after Identification of the First Strain (H041) with High-Level Ceftriaxone Resistance. Antimicrobial Agents and Chemotherapy, 2013, 57, 5225-5232.	3.2	88
277	Identification of Amino Acids Conferring High-Level Resistance to Expanded-Spectrum Cephalosporins in the penA Gene from Neisseria gonorrhoeae Strain H041. Antimicrobial Agents and Chemotherapy, 2013, 57, 3029-3036.	3.2	58
278	Evolution ofNeisseria gonorrhoeaeis a continuing challenge for molecular detection of gonorrhoea: false negative gonococcalporAmutants are spreading internationally. Sexually Transmitted Infections, 2013, 89, 197-201.	1.9	33
279	The new variant ofChlamydia trachomatiswas present as early as 2003 in Ã–rebro County, Sweden, but remained undetected until 2006. Sexually Transmitted Infections, 2013, 89, 607-608.	1.9	10
280	O03.1â€…Risk Factors For Antimicrobial ResistantNeisseria Gonorrhoeaein Europe: Abstract O03.1 Table 1. Sexually Transmitted Infections, 2013, 89, A30.2-A30.	1.9	1
281	Analytical Evaluation of GeneXpert CT/NG, the First Genetic Point-of-Care Assay for Simultaneous Detection of Neisseria gonorrhoeae and Chlamydia trachomatis. Journal of Clinical Microbiology, 2013, 51, 1945-1947.	3.9	70
282	P1.019â€…Identification of the Amino Acids Conferring High-Level Resistance to Expanded-Spectrum Cephalosporins in thepenAGene from theNeisseria GonorrhoeaeStrain H041. Sexually Transmitted Infections, 2013, 89, A79.2-A79.	1.9	0
283	P3.152â€…Prevalence of Neisseria Gonorrhoeae Infection in Two Distinct Men-Who-Have-Sex-With-Men (MSM) Populations in Slovenia in 2012. Sexually Transmitted Infections, 2013, 89, A195.1-A195.	1.9	0
284	P3.292â€…The 2013 IUSTI European Collaborative Clinical Group (ECCG) Report on the Diagnosis and Management of Chlamydial Infections in Europe. Sexually Transmitted Infections, 2013, 89, A240.1-A240.	1.9	0
285	O21.3â€…Fitness Studies onNeisseria GonorrhoeaeHarboring MosaicpenAAlleles from Ceftriaxone-Resistant Isolates Predict the Spread of Resistance to Extended-Spectrum Cephalosporins. Sexually Transmitted Infections, 2013, 89, A67.2-A67.	1.9	2
286	P1.018â€…Analysis of Mosaic Penicillin-Binding Protein 2 Variants with Ala501 Mutations That Confer High-Level Resistance to Expanded-Spectrum Cephalosporins inNeisseria Gonorrhoeae. Sexually Transmitted Infections, 2013, 89, A79.1-A79.	1.9	0
287	P5.077â€…Nucleic Acid Amplification Test (NAAT) Diagnostics Combined with DelayedNeisseria GonorrhoeaeCultivation of NAAT Positive Samples Using the ESwabâ„¢ System - the Solution For Future Gonococcal Antimicrobial Susceptibility Surveillance?. Sexually Transmitted Infections, 2013, 89, A358.3-A359.	1.9	1
288	P5.081â€…Analytical Evaluation of the GeneXpert^{Â®}CT/NG, the First Genetic Point of Care Assay For Simultaneous Detection ofNeisseria GonorrhoeaeandChlamydia Trachomatis. Sexually Transmitted Infections, 2013, 89, A360.1-A360.	1.9	0

#	Article	IF	Citations
289	Second European Multi-Disciplinary Conference of National Strategies for Chlamydia Trachomatis and Human Papillomavirus (NSCP Conference) in Berlin, 2013 â€" Enhanced Detection, Management and Surveillance of Sexually Transmitted Infections in Europe are Essential!. International Journal of Immunopathology and Pharmacology, 2013, 26, 839-845.	2.1	0
290	Analytical Specificity and Sensitivity of the APTIMA Combo 2 and APTIMA GC Assays for Detection of Commensal Neisseria Species and Neisseria gonorrhoeae on the Gen-Probe Panther Instrument. Sexually Transmitted Diseases, 2013, 40, 175-178.	1.7	17
291	P5.064â€...Preliminary Analytical Evaluation of ArtusÂ® CT/NG, For Simultaneous Detection ofNeisseria GonorrhoeaeandChlamydia Trachomatis. Sexually Transmitted Infections, 2013, 89, A354.3-A355.	1.9	0
292	P1.020â€...Phenotypic and Genetic Characterization of the First Three Cases of Extended-Spectrum Cephalosporin ResistantNeisseria GonorrhoeaeInfection in South Africa and Association with Cefixime Treatment Failure. Sexually Transmitted Infections, 2013, 89, A79.3-A80.	1.9	0
293	Composition of the Vaginal Microbiota in Women of Reproductive Age â€" Sensitive and Specific Molecular Diagnosis of Bacterial Vaginosis Is Possible?. PLoS ONE, 2013, 8, e60670.	2.5	184
294	Molecular epidemiological typing within the European Gonococcal Antimicrobial Resistance Surveillance Programme reveals predominance of a multidrug-resistant clone. Eurosurveillance, 2013, 18, .	7.0	110
295	Molecular epidemiological typing within the European Gonococcal Antimicrobial Resistance Surveillance Programme reveals predominance of a multidrug-resistant clone. Eurosurveillance, 2013, 18, .	7.0	55
296	First Reported Case of the Swedish New Variant of Chlamydia trachomatis (nvCT) in Eastern Europe (Russia), and Evaluation of Russian Nucleic Acid Amplification Tests Regarding Their Ability to Detect nvCT. Acta Dermato-Venereologica, 2012, 92, 330-331.	1.3	8
297	Appropriate Time for Test-of-Cure when Diagnosing Gonorrhoea with a Nucleic Acid Amplification Test. Acta Dermato-Venereologica, 2012, 92, 316-319.	1.3	17
298	Evaluation of Neisseria gonorrhoeae Multiple-Locus Variable-Number Tandem-Repeat Analysis, N. gonorrhoeae Multiantigen Sequence Typing, and Full-LengthporBGene Sequence Analysis for Molecular Epidemiological Typing. Journal of Clinical Microbiology, 2012, 50, 180-183.	3.9	9
299	Phenotypic and genetic characterisation of bacterial sexually transmitted infections in Bissau, Guinea-Bissau, West Africa: a prospective cohort study. BMJ Open, 2012, 2, e000636.	1.9	13
300	The serious threat of multidrug-resistant and untreatable gonorrhoea: the pressing need for global action to control the spread of antimicrobial resistance, and mitigate the impact on sexual and reproductive health. Sexually Transmitted Infections, 2012, 88, 317-318.	1.9	53
301	In Vitro Activity of Ertapenem versus Ceftriaxone against Neisseria gonorrhoeae Isolates with Highly Diverse Ceftriaxone MIC Values and Effects of Ceftriaxone Resistance Determinants: Ertapenem for Treatment of Gonorrhea?. Antimicrobial Agents and Chemotherapy, 2012, 56, 3603-3609.	3.2	63
302	In Vitro Activity of the New Fluoroketolide Solithromycin (CEM-101) against a Large Collection of Clinical Neisseria gonorrhoeae Isolates and International Reference Strains, Including Those with High-Level Antimicrobial Resistance: Potential Treatment Option for Gonorrhea?. Antimicrobial Agents and Chemotherapy, 2012, 56, 2739-2742.	3.2	90
303	Clonally Related Neisseria gonorrhoeae Isolates with Decreased Susceptibility to the Extended-Spectrum Cephalosporin Cefotaxime in Amsterdam, the Netherlands. Antimicrobial Agents and Chemotherapy, 2012, 56, 1516-1522.	3.2	27
304	Reply to â€œManagement of Pharyngeal Gonorrhea Is Crucial To Prevent the Emergence and Spread of Antibiotic-Resistant Neisseria gonorrhoeaeâ€• Antimicrobial Agents and Chemotherapy, 2012, 56, 4041-4042.	3.2	3
305	Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiology, 2012, 7, 1401-1422.	2.0	367
306	High-Level Cefixime- and Ceftriaxone-Resistant Neisseria gonorrhoeae in France: Novel penA Mosaic Allele in a Successful International Clone Causes Treatment Failure. Antimicrobial Agents and Chemotherapy, 2012, 56, 1273-1280.	3.2	546

#	Article	IF	Citations
307	Molecular Analyses of TEM Genes and Their Corresponding Penicillinase-Producing Neisseria gonorrhoeae Isolates in Bangkok, Thailand. Antimicrobial Agents and Chemotherapy, 2012, 56, 916-920.	3.2	46
308	Genome Sequencing of a Neisseria gonorrhoeae Isolate of a Successful International Clone with Decreased Susceptibility and Resistance to Extended-Spectrum Cephalosporins. Antimicrobial Agents and Chemotherapy, 2012, 56, 5633-5641.	3.2	31
309	Multilocus sequence typing and repetitive-sequence-based PCR (DiversiLab) for molecular epidemiological characterization of Propionibacterium acnes isolates of heterogeneous origin. Anaerobe, 2012, 18, 392-399.	2.1	14
310	Whole-genome analysis of diverse Chlamydia trachomatis strains identifies phylogenetic relationships masked by current clinical typing. Nature Genetics, 2012, 44, 413-419.	21.4	279
311	Phenotypic and genotypic properties of Neisseria gonorrhoeae isolates in Norway in 2009: antimicrobial resistance warrants an immediate change in national management guidelines. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 1181-1186.	2.9	18
312	Novel meningococcal 4<scp>CM</scp>enB vaccine antigens â€“ prevalence and polymorphisms of the encoding genes in Neisseria gonorrhoeae. Apmis, 2012, 120, 750-760.	2.0	31
313	Antibiotic susceptibility in prostateâ€derived Propionibacterium acnes isolates. Apmis, 2012, 120, 778-785.	2.0	20
314	Clinical Neisseria gonorrhoeae isolate with a N. meningitidis porA gene and no prolyliminopeptidase activity, Sweden, 2011 â€“ danger of false-negative genetic and culture diagnostic results. Eurosurveillance, 2012, 17, .	7.0	14
315	Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011. Eurosurveillance, 2012, 17, .	7.0	72
316	Recent trends in gonorrhoea and syphilis epidemiology in Sweden: 2007 to 2011. Eurosurveillance, 2012, 17, .	7.0	17
317	The â€˜2012 European guideline on the diagnosis and treatment of gonorrhoea in adultsâ€™ recommends dual antimicrobial therapy. Eurosurveillance, 2012, 17, .	7.0	41
318	Clinical Neisseria gonorrhoeae isolate with a N. meningitidis porA gene and no prolyliminopeptidase activity, Sweden, 2011: danger of false-negative genetic and culture diagnostic results. Eurosurveillance, 2012, 17, .	7.0	6
319	Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011. Eurosurveillance, 2012, 17, .	7.0	47
320	Is Neisseria gonorrhoeae Initiating a Future Era of Untreatable Gonorrhea?: Detailed Characterization of the First Strain with High-Level Resistance to Ceftriaxone. Antimicrobial Agents and Chemotherapy, 2011, 55, 3538-3545.	3.2	600
321	Resistance to Azithromycin of Neisseria gonorrhoeae Isolates From 2 Cities in China. Sexually Transmitted Diseases, 2011, 38, 764-768.	1.7	22
322	S15.2 European gonococcal antimicrobial surveillance programme (Euro-GASP): towards timelier monitoring. Sexually Transmitted Infections, 2011, 87, A19-A19.	1.9	1
323	P3-S1.22 Evaluation of performance of six commercial assays for detection of characterised isolates of Neisseria gonorrhoeae and other Neisseria spp.. Sexually Transmitted Infections, 2011, 87, A274-A275.	1.9	0
324	O1-S03.03 Clonally related Neisseria gonorrhoeae isolates with decreased susceptibility to extended-spectrum cephalosporins in Amsterdam, the Netherlands. Sexually Transmitted Infections, 2011, 87, A26-A27.	1.9	0

#	Article	IF	Citations
325	The Swedish new variant of Chlamydia trachomatis. Current Opinion in Infectious Diseases, 2011, 24, 62-69.	3.1	70
326	Prevalence trends in Sweden for the new variant of Chlamydia trachomatis. Clinical Microbiology and Infection, 2011, 17, 683-689.	6.0	23
327	Cefpodoxime 10â€ƒÎ¼g disc screening test for detection of Neisseria gonorrhoeae with mosaic PBP2 and decreased susceptibility to extended-spectrum cephalosporins for public health purposes. Apmis, 2011, 119, 356-363.	2.0	4
328	Antimicrobial susceptibility/resistance and molecular epidemiological characteristics of Neisseria gonorrhoeae in 2009 in Belarus. Apmis, 2011, 119, 537-542.	2.0	9
329	Gonorrhoea surveillance, laboratory diagnosis and antimicrobial susceptibility testing of Neisseria gonorrhoeae in 11 countries of the eastern part of the WHO European region. Apmis, 2011, 119, 643-649.	2.0	14
330	The evolution of infectious agents in relation to sex in animals and humans: brief discussions of some individual organisms. Annals of the New York Academy of Sciences, 2011, 1230, 74-107.	3.8	5
331	Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution, and lessons learned for the future. Annals of the New York Academy of Sciences, 2011, 1230, E19-28.	3.8	174
332	HIV, STI prevalence and risk behaviours among women selling sex in Lahore, Pakistan. BMC Infectious Diseases, 2011, 11, 119.	2.9	29
333	A Novel Mechanism of High-Level, Broad-Spectrum Antibiotic Resistance Caused by a Single Base Pair Change in Neisseria gonorrhoeae. MBio, 2011, 2, .	4.1	77
334	Evaluation of Six Commercial Nucleic Acid Amplification Tests for Detection of Neisseria gonorrhoeae and Other Neisseria Species. Journal of Clinical Microbiology, 2011, 49, 3610-3615.	3.9	110
335	Review and International Recommendation of Methods for Typing Neisseria gonorrhoeae Isolates and Their Implications for Improved Knowledge of Gonococcal Epidemiology, Treatment, and Biology. Clinical Microbiology Reviews, 2011, 24, 447-458.	13.6	127
336	An evaluation of gentamicin susceptibility of Neisseria gonorrhoeae isolates in Europe. Journal of Antimicrobial Chemotherapy, 2011, 66, 592-595.	3.0	63
337	Laboratory Diagnosis of Sexually Transmitted Infections in Belarus. Acta Dermato-Venereologica, 2011, 91, 64-65.	1.3	3
338	Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Eurosurveillance, 2011, 16, .	7.0	111
339	The European gonococcal antimicrobial surveillance programme, 2009. Eurosurveillance, 2011, 16, .	7.0	32
340	First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. Eurosurveillance, 2011, 16, .	7.0	96
341	Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Eurosurveillance, 2011, 16, .	7.0	60
342	The European gonococcal antimicrobial surveillance programme, 2009. Eurosurveillance, 2011, 16, .	7.0	17

#	Article	IF	Citations
343	First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. Eurosurveillance, 2011, 16, .	7.0	62
344	Distribution of Chlamydia trachomatis ompA genovars and the new variant of C. trachomatis in the GÃ¶teborg area, Sweden. European Journal of Clinical Microbiology and Infectious Diseases, 2010, 29, 609-611.	2.9	10
345	Propionibacterium acnes as an etiological agent of arthroplastic and osteosynthetic infections â€“ Two cases with specific clinical presentation including formation of draining fistulae. Anaerobe, 2010, 16, 304-306.	2.1	22
346	Guidelines for the laboratory diagnosis of trichomoniasis in East European countries. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 1125-1134.	2.4	25
347	Guidelines for the Laboratory Diagnosis of Mycoplasma genitalium Infections in East European Countries. Acta Dermato-Venereologica, 2010, 90, 461-467.	1.3	24
348	Alterations of the pilQ gene in Neisseria gonorrhoeae are unlikely contributors to decreased susceptibility to ceftriaxone and cefixime in clinical gonococcal strains. Journal of Antimicrobial Chemotherapy, 2010, 65, 2543-2547.	3.0	38
349	Characterisation of Chlamydia trachomatis by ompA sequencing and multilocus sequence typing in a Swedish county before and after identification of the new variant. Sexually Transmitted Infections, 2010, 86, 56-60.	1.9	32
350	Recommended antimicrobial treatment of uncomplicated gonorrhoea in 2009 in 11 East European countries: implementation of a Neisseria gonorrhoeae antimicrobial susceptibility programme in this region is crucial. Sexually Transmitted Infections, 2010, 86, 442-444.	1.9	28
351	The Swedish new variant of Chlamydia trachomatis: genome sequence, morphology, cell tropism and phenotypic characterization. Microbiology (United Kingdom), 2010, 156, 1394-1404.	1.8	81
352	Emergence, spread and characteristics of Neisseria gonorrhoeae isolates with in vitro decreased susceptibility and resistance to extended-spectrum cephalosporins in Sweden. Sexually Transmitted Infections, 2010, 86, 454-460.	1.9	80
353	Emergence of the new variant of Chlamydia trachomatis in a defined area of Sweden before 2002?. Sexually Transmitted Infections, 2010, 86, 337-341.	1.9	6
354	Molecular and Structural Analysis of Mosaic Variants of Penicillin-Binding Protein 2 Conferring Decreased Susceptibility to Expanded-Spectrum Cephalosporins in Neisseria gonorrhoeae: Role of Epistatic Mutations. Biochemistry, 2010, 49, 8062-8070.	2.5	114
355	The Russian gonococcal antimicrobial susceptibility programme (RU-GASP) â€“ national resistance prevalence in 2007 and 2008, and trends during 2005-2008. Eurosurveillance, 2010, 15, .	7.0	45
356	Authorâ€™s reply: The Russian gonococcal antimicrobial susceptibility programme (RU-GASP)--national resistance prevalence in 2007 and 2008, and trends during 2005-2008. Eurosurveillance, 2010, 15, .	7.0	1
357	Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Eurosurveillance, 2010, 15, .	7.0	143
358	The Russian gonococcal antimicrobial susceptibility programme (RU-GASP)--national resistance prevalence in 2007 and 2008, and trends during 2005-2008. Eurosurveillance, 2010, 15, .	7.0	21
359	Evaluation of the new COBAS TaqMan CT test v2.0 and impact on the proportion of new variant Chlamydia trachomatis by the introduction of diagnostics detecting new variant C trachomatis in Orebro county, Sweden. Sexually Transmitted Infections, 2009, 85, 190-193.	1.9	14
360	Genetics of Chromosomally Mediated Intermediate Resistance to Ceftriaxone and Cefixime in Neisseria gonorrhoeae. Antimicrobial Agents and Chemotherapy, 2009, 53, 3744-3751.	3.2	139

#	Article	IF	Citations
361	Antibiotic Susceptibility and Characteristics of Neisseria meningitidis Isolates from the African Meningitis Belt, 2000 to 2006: Phenotypic and Genotypic Perspectives. Antimicrobial Agents and Chemotherapy, 2009, 53, 1561-1566.	3.2	32
362	Quality enhancements of laboratory diagnosis of sexually transmitted infections in Russia. International Journal of STD and AIDS, 2009, 20, 292-294.	1.1	0
363	Quality enhancements and quality assurance of laboratory diagnosis of sexually transmitted infections in Eastern Europe. International Journal of STD and AIDS, 2009, 20, 365-367.	1.1	13
364	Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. Journal of Antimicrobial Chemotherapy, 2009, 63, 1142-1151.	3.0	208
365	Simultaneous species identification and detection of rifampicin resistance in staphylococci by sequencing of the rpoB gene. European Journal of Clinical Microbiology and Infectious Diseases, 2009, 28, 183-190.	2.9	23
366	Prevalence, phenotypic and genetic characteristics of prolyliminopeptidaseâ€negative Neisseria gonorrhoeae isolates in Sweden during 2000â€“2007. Apmis, 2009, 117, 900-904.	2.0	3
367	First evaluation of six nucleic acid amplification tests widely used in the diagnosis of Chlamydia trachomatis in Russia. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 268-276.	2.4	30
368	Populationâ€based assessment of Mycoplasma genitalium in Vietnam â€“ low prevalence among married women of reproductive age in a rural area. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 533-537.	2.4	16
369	First evaluation of polymerase chain reaction assays used for diagnosis of Mycoplasma genitalium in Russia. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 1164-1172.	2.4	21
370	Evaluation of six nucleic acid amplification tests used for diagnosis ofNeisseria gonorrhoeaein Russia compared with an international strictly validated real-timeporApseudogene polymerase chain reaction. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 1246-1253.	2.4	19
371	Guidelines for the laboratory diagnosis of Chlamydia trachomatis infections in East European countries. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 1353-1363.	2.4	20
372	Meeting the public health challenge of multidrug- and extensively drug-resistantNeisseria gonorrhoeae. Expert Review of Anti-Infective Therapy, 2009, 7, 821-834.	4.4	250
373	Can the Swedish new variant of Chlamydia trachomatis (nvCT) be detected by UK NEQAS participants from seventeen European countries and five additional countries/regions in 2009?. Eurosurveillance, 2009, 14, .	7.0	16
374	The Swedish new variant of Chlamydia trachomatis (nvCT) remains undetected by many European laboratories as revealed in the recent PCR/NAT ring trial organised by INSTAND e.V., Germany. Eurosurveillance, 2009, 14, .	7.0	10
375	National surveillance of antimicrobial susceptibility in Neisseria gonorrhoeae in 2005-2006 and recommendations of first-line antimicrobial drugs for gonorrhoea treatment in Russia. Sexually Transmitted Infections, 2008, 84, 285-289.	1.9	26
376	The Neisseria gonorrhoeae population in Sweden during 2005â€”phenotypes, genotypes and antibiotic resistance. Apmis, 2008, 116, 181-189.	2.0	16
377	Comparison of microscopy, culture and inâ€house PCR and NASBA assays for diagnosis of Neisseria gonorrhoeae in Russia. Apmis, 2008, 116, 133-138.	2.0	14
378	Realâ€time PCR and subsequent pyrosequencing for screening of penA mosaic alleles and prediction of reduced susceptibility to expandedâ€spectrum cephalosporins in Neisseria gonorrhoeae. Apmis, 2008, 116, 1004-1008.	2.0	13

#	Article	IF	Citations
379	Laboratory diagnostics for non-viral sexually transmitted infections in St. Petersburg, Russia: current situation and hallmarks for improvements. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 1094-1100.	2.4	18
380	Home sampling and pooling of vaginal samples are effective tools for genetic screening of Chlamydia trachomatis among high school female students in Lithuania. Scandinavian Journal of Infectious Diseases, 2008, 40, 88-93.	1.5	10
381	Reproductive tract infections including sexually transmitted infections: a population-based study of women of reproductive age in a rural district of Vietnam. Sexually Transmitted Infections, 2008, 84, 126-132.	1.9	58
382	Combined Real-Time PCR and Pyrosequencing Strategy for Objective, Sensitive, Specific, and High-Throughput Identification of Reduced Susceptibility to Penicillins in Neisseria meningitidis. Antimicrobial Agents and Chemotherapy, 2008, 52, 753-756.	3.2	7
383	Clinical Validation of a Real-Time Polymerase Chain Reaction Detection of Neisseria gonorrheae porA Pseudogene Versus Culture Techniques. Sexually Transmitted Diseases, 2008, 35, 517-520.	1.7	21
384	Neisseria gonorrhoeae Isolates with Reduced Susceptibility to Cefixime and Ceftriaxone: Association with Genetic Polymorphisms in penA , mtrR , porB1b , and ponA. Antimicrobial Agents and Chemotherapy, 2007, 51, 2117-2122.	3.2	186
385	Antibiotic susceptibility of Neisseriagonorrhoeae in Arkhangelsk, Russia. Sexually Transmitted Infections, 2007, 83, 133-135.	1.9	16
386	Mutations in fusA Associated with Posttherapy Fusidic Acid Resistance in Clostridium difficile. Antimicrobial Agents and Chemotherapy, 2007, 51, 1840-1843.	3.2	19
387	Neisseria gonorrhoeae population in Arkhangelsk, Russia: phenotypic and genotypic heterogeneity. Clinical Microbiology and Infection, 2007, 13, 873-878.	6.0	29
388	Molecular characterization of Neisseria gonorrhoeae identifies transmission and resistance of one ciprofloxacin-resistant strain. Apmis, 2007, 115, 231-241.	2.0	45
389	Genetic homogeneity/heterogeneity of Propionibacterium acnes isolated from patients during cardiothoracic reoperation. Anaerobe, 2007, 13, 121-126.	2.1	17
390	Connector Inversion Probe Technology: A Powerful One-Primer Multiplex DNA Amplification System for Numerous Scientific Applications. PLoS ONE, 2007, 2, e915.	2.5	38
391	Experiences with the new genetic variant of Chlamydia trachomatis in Ã–rebro county, Sweden â€“ proportion, characteristics and effective diagnostic solution in an emergent situation. Eurosurveillance, 2007, 12, 5-6.	7.0	32
392	A Fast Real-Time Polymerase Chain Reaction Method for Sensitive and Specific Detection of the Neisseria gonorrhoeae porA Pseudogene. Journal of Molecular Diagnostics, 2006, 8, 574-581.	2.8	59
393	Transformation of ciprofloxacin-resistant Neisseria gonorrhoeae gyrA, parE and porB1b genes. International Journal of Antimicrobial Agents, 2006, 28, 206-211.	2.5	9
394	Molecular epidemiology of Neisseria gonorrhoeae- identification of the first presumed Swedish transmission chain of an azithromycin-resistant strain. Apmis, 2006, 114, 67-71.	2.0	19
395	Diagnosis of Chlamydia trachomatis in Russia ? in-house PCR assays may be effective but overall optimization and quality assurance are urgently needed. Apmis, 2006, 114, 500-507.	2.0	11
396	Global transmission of prolyliminopeptidase-negative Neisseria gonorrhoeae strains: implications for changes in diagnostic strategies. Sexually Transmitted Infections, 2006, 83, 47-51.	1.9	29

#	Article	IF	Citations
397	Total Variation in the penA Gene of Neisseria meningitidis : Correlation between Susceptibility to Î²-Lactam Antibiotics and penA Gene Heterogeneity. Antimicrobial Agents and Chemotherapy, 2006, 50, 3317-3324.	3.2	61
398	Laboratory diagnosis of Neisseria gonorrhoeae in St Petersburg, Russia: inventory, performance characteristics and recommended optimisations. Sexually Transmitted Infections, 2006, 82, 41-44.	1.9	22
399	Diagnosis of non-viral sexually transmitted infections in Lithuania and international recommendations. Eurosurveillance, 2006, 11, 9-10.	7.0	9
400	The porA pseudogene of Neisseria gonorrhoeae- low level of genetic polymorphism and a few, mainly identical, inactivating mutations. Apmis, 2005, 113, 410-419.	2.0	23
401	Phenotypic and genotypic characterization of prolyliminopeptidase-negative Neisseria gonorrhoeae isolates in Denmark. European Journal of Clinical Microbiology and Infectious Diseases, 2005, 24, 280-283.	2.9	11
402	Genotypic and Phenotypic Stability of Helicobacter pylori Markers in a Nine-Year Follow-up Study of Patients with Noneradicated Infection. Digestive Diseases and Sciences, 2005, 50, 375-380.	2.3	7
403	The Sialic Acid Binding SabA Adhesin of Helicobacter pylori Is Essential for Nonopsonic Activation of Human Neutrophils. Journal of Biological Chemistry, 2005, 280, 15390-15397.	3.4	99
404	Laboratory Diagnosis of Sexually Transmitted Infections in Estonia in 2001â€“2002: Shortcomings With Impact on Diagnostic Quality and Surveillance. Sexually Transmitted Diseases, 2005, 32, 759-764.	1.7	13
405	Detection of gyrA mutations associated with ciprofloxacin resistance in Neisseria gonorrhoeae by rapid and reliable pre-programmed short DNA sequencing. International Journal of Antimicrobial Agents, 2005, 26, 486-490.	2.5	23
406	Molecular Typing of Neisseria gonorrhoeae Isolates by Pyrosequencing of Highly Polymorphic Segments of the porB Gene. Journal of Clinical Microbiology, 2004, 42, 2926-2934.	3.9	25
407	Molecular genetic methods for diagnosis and characterisation of Chlamydia trachomatis and Neisseria gonorrhoeae: impact on epidemiological surveillance and interventions. Apmis, 2004, 112, 771-784.	2.0	45
408	Analysis of PorA variable region 3 in meningococci: implications for vaccine policy?. Vaccine, 2003, 21, 2468-2473.	3.8	26
409	Comparison of Serologic and Genetic porB -Based Typing of Neisseria gonorrhoeae : Consequences for Future Characterization. Journal of Clinical Microbiology, 2003, 41, 4141-4147.	3.9	33
410	One year of Neisseria gonorrhoeae isolates in Sweden: the prevalence study of antibiotic susceptibility shows relation to the geographic area of exposure. International Journal of STD and AIDS, 2002, 13, 109-114.	1.1	36
411	Molecular Epidemiology of Neisseria gonorrhoeae : Sequence Analysis of the porB Gene Confirms Presence of Two Circulating Strains. Journal of Clinical Microbiology, 2002, 40, 3741-3749.	3.9	46
412	Pulsed-Field Gel Electrophoresis as an Epidemiologic Tool for Neisseria gonorrhoeae. Sexually Transmitted Diseases, 2002, 29, 25-31.	1.7	18
413	Genosubtyping by sequencing group A, B and C meningococci; a tool for epidemiological studies of epidemics, clusters and sporadic casesNote. Apmis, 2000, 108, 509-516.	2.0	21
414	Performance of the first commercial dual resistance assay, AmpliSens Mycoplasma genitalium-ML/FQ-Resist-FL, for detection of potential macrolide and quinolone resistance-associated mutations and prevalence of M. genitalium resistance mutations in St. Petersburg, Russia. Sexually Transmitted Infections, 0, , sextrans-2021-055249.	1.9	3

#	Article	IF	Citations
415	Unencapsulated penicillin-resistant Neisseria meningitidis ST-53 clonal complex strain causing symptomatic proctitis in an HIV-negative man who has sex with men: A case report. International Journal of STD and AIDS, 0, , 095646242211136.	1.1	0